CC0 PUBLIC RECORD GRAPH Every score & timeline item links directly to its underlying U.S. FDA record (openFDA, ORA FOIA Reading Room, DECRS & OASIS).
FG
GMPGraphv2.0
Global FDA Facility Graph & Co-Packer Intelligence
Form 483 Library → Therapak Corporation → 483-3010882984-20260212
Form FDA 483 · Issued 2026-02-12

Therapak Corporation — FDA Form 483 Analysis

FEI: 3010882984 · Sector: Pharmaceuticals & Sterile/OTC Drugs (Contract Manufacturer) · Lead Investigator: Marcus V. Delgado

FDA Form 483 issued to Therapak Corporation (FEI 3010882984) on 2026-02-12 following an inspection of its contract manufacturer operations in California. The report documents 2 inspection observations centered on Finished Product Testing, Stability & Expiration Dating, Electronic Record Data Integrity (21 CFR Part 11) & Retention.

Get Full Annotated 483 Dossier + CAPA Checklist
Instant PDF + CFR Matrix ($79 vs. Redica's $289)
Buy Dossier ($79)
Need Help Fixing These 2 Citations?
Get matched with a vetted 21 CFR remediation consultant
Request Consultant

Observation-by-Observation 21 CFR Breakdown (2)

Observation #1 · 21 CFR 212.60(c) Finished Product Testing, Stability & Expiration Dating
FIRST-TIME OBSERVATION
Analytical methods
Inspector Observation Language: "Your laboratory analytical methods are not [suitable for their intended use] [sufficiently sensitive] [sufficiently specific] [sufficiently accurate] [sufficiently reproducible]. Specifically, observed during inspection of Therapak Corporation on 2026-02-12."
Plain-English Meaning: Releasing finished batches without verifying strength/potency/microbiological specs, or placing an expiration/best-by date on labels without supporting real-time or accelerated stability data.
Standard CAPA Remediation Path: Require finished-batch microbiological (USP <2021>/<2022>), heavy metal, and active-assay release testing plus ICH stability chamber protocols supporting every label shelf-life claim.
Observation #2 · 21 CFR 212.110(b) Electronic Record Data Integrity (21 CFR Part 11) & Retention
FIRST-TIME OBSERVATION
Record quality
Inspector Observation Language: "All records including those not stored at your inspected establishment are not [legible] [stored to prevent deterioration or loss] [readily available for review and copying by FDA employees]. Specifically,observed during inspection of Therapak Corporation on 2026-02-12."
Plain-English Meaning: Uncontrolled spreadsheets, shared laboratory logins, missing audit trails, backdated entries, or failure to retain batch and distribution records for the statutory window.
Standard CAPA Remediation Path: Enforce unique user credentials, immutable audit trails on analytical instruments, controlled form issuance numbers, and 2-year post-expiration record retention.